Try Alerts Free   |   Login
Health Care › Electronic Computers

OMCL Price Correlated With Financials For Omnicell

Free historical financial statements for Omnicell Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with OMCL stock chart to see long term trends.

OMCL Stock Compared to Quarterly

OMCL Income Statement

Revenue, Net:318828000
Revenue Per Share:7.2053
Cost of Goods & Services Sold:168781000
Gross Profit:150047000
Selling, General & Admin Expense:119933000
Research & Development Expense:25030000
Total Operating Expenses:144963000
Operating Income:5084000
Income Taxes:-3243000
Net Income:8213000
Earnings Per Share, Basic:0.19
Shares Outstanding, Basic Avg:44249000

OMCL Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:21124000
Net Cash from Operations:-15996000
Net Cash from Operations Per Share:-0.3615
Repurchases/Buybacks Common Stock:52210000
Net Cash from Financing Activities:-32119000
Property, Plant & Equipment Purchases:11489000
Purchases of Businesses, Net of Cash:3392000
Net Cash from Investing Activities:-18733000
Net Change in Cash & Equivalents:-67259000

OMCL Balance Sheet

Cash and Cash Equivalents:288361000
Inventories:137056000
Total Current Assets:775604000
Property, Plant & Equipment, Net:77062000
Total Assets:2122588000
Accounts Payable:71645000
Total Short-Term Liabilities:951012000
Total Liabilities:1047847000
COMPANY PROFILE
Organization and Summary of Significant Accounting Policies Business

Omnicell, Inc. was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. The Company’s major products and related services are medication management solutions and adherence tools for healthcare systems and pharmacies, which are sold in its principal market, the healthcare industry. The Company’s market is primarily located in the United States and Europe. “Omnicell” or the “Company” collectively refer to Omnicell, Inc. and its subsidiaries.

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s consolidated financial position, results of operations, and cash flows for the periods presented.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

On September 9, 2021, the Company completed its acquisition of RxInnovation Inc., operating as FDS Amplicare (“FDS Amplicare”); on December 29, 2021, the Company completed its acquisition of ReCept Holdings, Inc. (“ReCept”); and on December 31, 2021, the Company completed its acquisition of MarkeTouch Media, LLC (“MarkeTouch Media”). The Consolidated Financial Statements include the results of operations of these recently acquired companies, commencing as of the respective acquisition dates. The significant accounting policies of the acquired businesses have been aligned to conform to the accounting policies of Omnicell.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company’s Consolidated Financial Statements and accompanying Notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the Company in the future, actual results may be different from the estimates. The Company’s critical accounting policies are those that affect its financial statements materially and involve difficult, subjective, or complex judgments by management. Those policies are revenue recognition; allowance for credit losses for accounts receivable and unbilled receivables; notes receivable from investment in sales-type leases; operating lease right-of-use assets and liabilities; inventory valuation; capitalized software development costs; impairment of goodwill; purchased intangibles and long-lived assets; fair value of assets acquired and liabilities assumed in business combinations; convertible senior notes; share-based compensation; and accounting for income taxes. As of December 31, 2021, the Company is not aware of any events or circumstances that would require an update to its estimates, judgments, or revisions to the carrying value of its assets or liabilities.

Segment Reporting

The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company at the consolidated level using information about its revenues, gross profit, income from operations, and other key financial data. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment.

Foreign Currency Translation and Remeasurement

Most of the Company’s foreign subsidiaries use the local currency of their respective countries as their functional curren

Data imported from Omnicell Inc SEC filings. Check original filings before making any investment decision.